Category - Developments

Developments

Profound Medical sees five-fold jump in preliminary Q4 revenue versus Q3

Profound Medical (TSX:PRN; OTCQX:PRFMF) expects total revenue of about $1.6-million for the fourth quarter of 2018, up from about $300,000 for the third quarter last year. For all of 2018, the company expects total...

January 4, 2019

Developments

Scientus Pharma receives Health Canada approval to sell dried cannabis

Closely-held Scientus Pharma received authorization under Health Canada’s cannabis regulations for the sale of cannabis for medical purposes and to modify its processor licence to sell dried and fresh cannabis products...

January 3, 2019

Developments

BeyondSpring has positive pre-NDA meeting at FDA about Plinabulin

BeyondSpring (NASDAQ:BYSI) had a positive pre-NDA meeting with the FDA about its lead asset, Plinabulin. The focus of this meeting was the content of the chemistry, manufacturing and control (CMC) sections of the...

December 27, 2018

Developments

BeyondSpring receives U.S. composition of matter patent for Plinabulin

BeyondSpring (NASDAQ:BYSI) received a new composition of matter patent for its lead asset, Plinabulin, from the U.S. Patent and Trademark Office. As a polymorph, Pinabulin can be converted into multiple crystalline...

December 21, 2018

Developments

Canopy Rivers affiliate gains traction in New Jersey medical cannabis market

Canopy Rivers (TSXV:RIV) announced that NETA NJ LLC, a company controlled by its portfolio company, TerrAscend (CSE:TER; OTCQX:TRSSF), has been selected by the State of New Jersey Department of Health to apply for final...

December 19, 2018

Developments

IntelGenx in pact with Gensco Pharma to market RIZAPORT in U.S.

IntelGenx (TSX-V:IGX; OTCQX:IGXT) signed a definitive licensing, development and supply agreement with Gensco Pharma, a specialty pharmaceutical company, for the exclusive commercialization of RIZAPORT in the U.S. “With...

December 12, 2018

Developments

LexaGene completes development of canine UTI syndromic panel

LexaGene Holdings (OTCQB:LXXGF; TSX-V:LXG) has completed development of a syndromic panel to detect urinary tract infection (UTI) in small animals. The assay is capable of detecting each of the eight most common...

December 12, 2018

Developments

Research finds cancer detection in 10-minute blood test

Researchers in Australia have developed a simple blood test they claim can diagnose cancer in 10 minutes by identifying a unique DNA signature present in all types of the disease. While the test has yet to be studied in...

December 6, 2018

Developments

Canopy Growth acquires Storz & Bickel for up to €145-million

Canopy Growth (TSX:WEED; NYSE:CGC) finalized an all-cash transaction to acquire Storz & Bickel GmbH for up to approximately €145-million. Storz & Bickel is widely recognized as the global leader in vaporizer...

December 6, 2018

Developments

BeyondSpring posts positive interim analysis of Plinabulin for chemotherapy-induced neutropenia

BeyondSpring (NASDAQ:BYSI) announced that the Phase 3 portion of its Study 105 evaluating its lead asset, Plinabulin, in patients treated with docetaxel chemotherapy has met its primary endpoint of non-inferiority...

December 6, 2018

Category - Developments

Profound Medical sees five-fold jump in preliminary Q4 revenue versus Q3

Scientus Pharma receives Health Canada approval to sell dried cannabis

BeyondSpring has positive pre-NDA meeting at FDA about Plinabulin

BeyondSpring receives U.S. composition of matter patent for Plinabulin

Canopy Rivers affiliate gains traction in New Jersey medical cannabis market

IntelGenx in pact with Gensco Pharma to market RIZAPORT in U.S.

LexaGene completes development of canine UTI syndromic panel

Research finds cancer detection in 10-minute blood test

Canopy Growth acquires Storz & Bickel for up to €145-million

BeyondSpring posts positive interim analysis of Plinabulin for chemotherapy-induced neutropenia

General

More